


Delineating the differences trastuzumab biosimilar development reviewed

Saturday 9 September 2017, 18.30–20.00

Tarragona Auditorium, Hall 9, IFEMA, Feria de Madrid, Madrid, Spain


Programme

Chair: William Gradishar, USA




Welcome and introduction

William Gradishar, USA




From processes to positions: regulatory framework and clinical opinion

Diana Lüftner, Germany




Applying the process: non-clinical and clinical design steps

Richard Markus, Amgen




Comparing the process: considering differences in the assessment of clinical similarity

Xavier Pivot, France



Delineating the differences: panel discussion

All



Concluding comments and close

William Gradishar, USA

